Search

Your search keyword '"Veronese C."' showing total 5 results
Start Over Author "Veronese C." Publication Type Electronic Resources
5 results on '"Veronese C."'

1. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres

Author

Cameli, P, Faverio, P, Ferrari, K, Bonti, V, Marsili, S, Mazzei, M, Mazzoni, F, Bartolucci, M, Scotti, V, Bertolini, F, Barbieri, F, Baldessari, C, Veronese, C, Boffi, R, Brighenti, M, Cortinovis, D, Dominici, M, Pesci, A, Bargagli, E, Luppi, F, Cameli P., Faverio P., Ferrari K., Bonti V., Marsili S., Mazzei M. A., Mazzoni F., Bartolucci M., Scotti V., Bertolini F., Barbieri F., Baldessari C., Veronese C., Boffi R., Brighenti M., Cortinovis D., Dominici M., Pesci A., Bargagli E., Luppi F., Cameli, P, Faverio, P, Ferrari, K, Bonti, V, Marsili, S, Mazzei, M, Mazzoni, F, Bartolucci, M, Scotti, V, Bertolini, F, Barbieri, F, Baldessari, C, Veronese, C, Boffi, R, Brighenti, M, Cortinovis, D, Dominici, M, Pesci, A, Bargagli, E, Luppi, F, Cameli P., Faverio P., Ferrari K., Bonti V., Marsili S., Mazzei M. A., Mazzoni F., Bartolucci M., Scotti V., Bertolini F., Barbieri F., Baldessari C., Veronese C., Boffi R., Brighenti M., Cortinovis D., Dominici M., Pesci A., Bargagli E., and Luppi F.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and radiological features and survival of a multicentre cohort of patients who developed ICI-related lung toxicity. Methods: Six Italian centres were involved in the study. Patients who were treated with anti-PD-1/PD-L1 and CTLA-4 mAbs and developed ICI-related lung toxicity were recruited retrospectively to study clinical, radiological, immunological and survival data. Results: A total of 41 patients (25 males, 66.8 ± 9.9 years) were enrolled. Lung toxicity occurred after 204.3 ± 208.3 days of therapy, with ground glass opacities being the most common HRCT pattern (23 cases). Male sex, lung cancer and acute respiratory failure were associated with a shorter latency of toxicity (p = 0.0030, p = 0.0245 and p = 0.0390, respectively). Patients who required high-flow oxygen therapy showed significantly worse survival (p = 0.0028). Conclusions: Our cohort showed heterogeneous clinical and radiological aspects of ICI-related lung toxicity, with a latency not limited to the first year of treatment. Severity was mainly mild to moderate, although life-threatening events did occur. Our data indicate that strict long-term follow-up is needed to enable early diagnosis and appropriate management.

Published
2022

2. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres

Author

Cameli, P, Faverio, P, Ferrari, K, Bonti, V, Marsili, S, Mazzei, M, Mazzoni, F, Bartolucci, M, Scotti, V, Bertolini, F, Barbieri, F, Baldessari, C, Veronese, C, Boffi, R, Brighenti, M, Cortinovis, D, Dominici, M, Pesci, A, Bargagli, E, Luppi, F, Cameli P., Faverio P., Ferrari K., Bonti V., Marsili S., Mazzei M. A., Mazzoni F., Bartolucci M., Scotti V., Bertolini F., Barbieri F., Baldessari C., Veronese C., Boffi R., Brighenti M., Cortinovis D., Dominici M., Pesci A., Bargagli E., Luppi F., Cameli, P, Faverio, P, Ferrari, K, Bonti, V, Marsili, S, Mazzei, M, Mazzoni, F, Bartolucci, M, Scotti, V, Bertolini, F, Barbieri, F, Baldessari, C, Veronese, C, Boffi, R, Brighenti, M, Cortinovis, D, Dominici, M, Pesci, A, Bargagli, E, Luppi, F, Cameli P., Faverio P., Ferrari K., Bonti V., Marsili S., Mazzei M. A., Mazzoni F., Bartolucci M., Scotti V., Bertolini F., Barbieri F., Baldessari C., Veronese C., Boffi R., Brighenti M., Cortinovis D., Dominici M., Pesci A., Bargagli E., and Luppi F.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and radiological features and survival of a multicentre cohort of patients who developed ICI-related lung toxicity. Methods: Six Italian centres were involved in the study. Patients who were treated with anti-PD-1/PD-L1 and CTLA-4 mAbs and developed ICI-related lung toxicity were recruited retrospectively to study clinical, radiological, immunological and survival data. Results: A total of 41 patients (25 males, 66.8 ± 9.9 years) were enrolled. Lung toxicity occurred after 204.3 ± 208.3 days of therapy, with ground glass opacities being the most common HRCT pattern (23 cases). Male sex, lung cancer and acute respiratory failure were associated with a shorter latency of toxicity (p = 0.0030, p = 0.0245 and p = 0.0390, respectively). Patients who required high-flow oxygen therapy showed significantly worse survival (p = 0.0028). Conclusions: Our cohort showed heterogeneous clinical and radiological aspects of ICI-related lung toxicity, with a latency not limited to the first year of treatment. Severity was mainly mild to moderate, although life-threatening events did occur. Our data indicate that strict long-term follow-up is needed to enable early diagnosis and appropriate management.

Published
2022

3. Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy)

Author

Cattaruzza, M, Gorini, G, Bosetti, C, Boffi, R, Lugo, A, Veronese, C, Carreras, G, Santucci, C, Stival, C, Pacifici, R, Zaga, V, Gallus, S, Giulietti, F, Sarzani, R, Spannella, F, Del Donno, M, Tartaglione, S, Marrazzo, G, Pelaia, G, D'Agosto, V, Berti, A, Voller, F, Cardellicchio, S, Cresci, C, Foschino Barbaro, M, De Palma, R, Negrini, S, Sicbaldi, V, Serafini, A, Bisconti, M, Refolo, L, Landoni, G, Rovere, P, Veronesi, G, Faverio, P, Garavello, W, Pesci, A, Giacobbe, R, Martucci, P, Parrella, R, Scarano, F, Aiello, M, Chetta, A, Franco, C, Mangia, A, Carrozzi, L, Maggi Monzani, F, Pistelli, F, Russo, P, Sanna, A, Barreca, F, Conti, V, Rossi, E, Ruli, M, Ruli, S, Varzaneh, S, Principe, R, Guerrini, S, Sebastiani, A, Galluccio, G, Pezzuto, A, Ricci, A, Casali, E, Mastroianni, C, Pirina, P, Polo, F, Beatrice, F, Romagnoli, M, Baraldo, M, Cojutti, P, Graziano, E, Pecori, D, Tascini, C, Tinghino, B, Cattaruzza M. S., Gorini G., Bosetti C., Boffi R., Lugo A., Veronese C., Carreras G., Santucci C., Stival C., Pacifici R., Zaga V., Gallus S., Giulietti F., Sarzani R., Spannella F., Del Donno M., Tartaglione S., Marrazzo G., Pelaia G., D'agosto V., Berti A., Voller F., Cardellicchio S., Cresci C., Foschino Barbaro M. P., De Palma R., Negrini S., Sicbaldi V., Serafini A., Bisconti M., Refolo L., Landoni G., Rovere P., Veronesi G., Faverio P., Garavello W., Pesci A., Giacobbe R., Martucci P., Parrella R., Scarano F., Aiello M., Chetta A., Franco C., Mangia A., Carrozzi L., Maggi Monzani F. F., Pistelli F., Russo P., Sanna A., Barreca F. M., Conti V., Rossi E., Ruli M., Ruli S., Varzaneh S. E., Principe R., Guerrini S., Sebastiani A., Galluccio G., Pezzuto A., Ricci A., Casali E., Mastroianni C., Pirina P., Polo F., Beatrice F., Romagnoli M., Baraldo M., Cojutti P. G., Graziano E., Pecori D., Tascini C., Tinghino B., Cattaruzza, M, Gorini, G, Bosetti, C, Boffi, R, Lugo, A, Veronese, C, Carreras, G, Santucci, C, Stival, C, Pacifici, R, Zaga, V, Gallus, S, Giulietti, F, Sarzani, R, Spannella, F, Del Donno, M, Tartaglione, S, Marrazzo, G, Pelaia, G, D'Agosto, V, Berti, A, Voller, F, Cardellicchio, S, Cresci, C, Foschino Barbaro, M, De Palma, R, Negrini, S, Sicbaldi, V, Serafini, A, Bisconti, M, Refolo, L, Landoni, G, Rovere, P, Veronesi, G, Faverio, P, Garavello, W, Pesci, A, Giacobbe, R, Martucci, P, Parrella, R, Scarano, F, Aiello, M, Chetta, A, Franco, C, Mangia, A, Carrozzi, L, Maggi Monzani, F, Pistelli, F, Russo, P, Sanna, A, Barreca, F, Conti, V, Rossi, E, Ruli, M, Ruli, S, Varzaneh, S, Principe, R, Guerrini, S, Sebastiani, A, Galluccio, G, Pezzuto, A, Ricci, A, Casali, E, Mastroianni, C, Pirina, P, Polo, F, Beatrice, F, Romagnoli, M, Baraldo, M, Cojutti, P, Graziano, E, Pecori, D, Tascini, C, Tinghino, B, Cattaruzza M. S., Gorini G., Bosetti C., Boffi R., Lugo A., Veronese C., Carreras G., Santucci C., Stival C., Pacifici R., Zaga V., Gallus S., Giulietti F., Sarzani R., Spannella F., Del Donno M., Tartaglione S., Marrazzo G., Pelaia G., D'agosto V., Berti A., Voller F., Cardellicchio S., Cresci C., Foschino Barbaro M. P., De Palma R., Negrini S., Sicbaldi V., Serafini A., Bisconti M., Refolo L., Landoni G., Rovere P., Veronesi G., Faverio P., Garavello W., Pesci A., Giacobbe R., Martucci P., Parrella R., Scarano F., Aiello M., Chetta A., Franco C., Mangia A., Carrozzi L., Maggi Monzani F. F., Pistelli F., Russo P., Sanna A., Barreca F. M., Conti V., Rossi E., Ruli M., Ruli S., Varzaneh S. E., Principe R., Guerrini S., Sebastiani A., Galluccio G., Pezzuto A., Ricci A., Casali E., Mastroianni C., Pirina P., Polo F., Beatrice F., Romagnoli M., Baraldo M., Cojutti P. G., Graziano E., Pecori D., Tascini C., and Tinghino B.

Abstract

The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results